Track market-moving stories before they get noisy

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. decreased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 12.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,419,221 shares of the company’s stock after selling 801,804 shares during the period. Amova Asset Management Americas Inc. owned about 1.03% of Recursion Pharmaceuticals worth $16,583,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in RXRX. Swiss National Bank increased its stake in Recursion Pharmaceuticals by 21.8% in the first quarter. Swiss National Bank now owns 877,000 shares of the company’s stock valued at $2,692,000 after acquiring an additional 156,700 shares during the last quarter. Ascent Wealth Partners LLC lifted its stake in Recursion Pharmaceuticals by 11.8% during the first quarter. Ascent Wealth Partners LLC now owns 28,081 shares of the company’s stock worth $86,000 after purchasing an additional 2,974 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Recursion Pharmaceuticals by 29.3% in the 1st quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock valued at $4,490,000 after purchasing an additional 331,048 shares in the last quarter. Ethos Financial Group LLC boosted its holdings in shares of Recursion Pharmaceuticals by 80.4% in the 1st quarter. Ethos Financial Group LLC now owns 23,486 shares of the company’s stock valued at $72,000 after purchasing an additional 10,466 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of Recursion Pharmaceuticals by 49.4% in the 1st quarter. Principal Financial Group Inc. now owns 33,161 shares of the company’s stock valued at $102,000 after purchasing an additional 10,959 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth A number of research analysts have recently commented on RXRX shares. JPMorgan Chase & Co. dropped their target price on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Morgan Stanley boosted their target price on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Finally, Wall Street Zen lowered Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $8.10.

View Our Latest Stock Report on RXRX

Insider Buying and Selling at Recursion Pharmaceuticals In related news, CEO Najat Khan sold 23,588 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $3.58, for a total value of $84,445.04. Following the transaction, the chief executive officer directly owned 2,175,796 shares in the company, valued at $7,789,349.68. This trade represents a 1.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total transaction of $158,400.00. Following the completion of the sale, the director directly owned 6,218,287 shares of the company’s stock, valued at approximately $24,624,416.52. The trade was a 0.64% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 131,937 shares of company stock worth $486,974. 6.65% of the stock is owned by insiders.

Recursion Pharmaceuticals Trading Down 1.7% NASDAQ:RXRX opened at $2.89 on Tuesday. The firm’s fifty day moving average is $3.32 and its 200-day moving average is $3.59. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47. Recursion Pharmaceuticals, Inc. has a 52 week low of $2.77 and a 52 week high of $7.18. The firm has a market cap of $1.53 billion, a P/E ratio of -2.41 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. The business had revenue of $6.47 million during the quarter, compared to the consensus estimate of $15.78 million. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. Recursion Pharmaceuticals’s quarterly revenue was down 56.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.50) earnings per share. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -0.99 earnings per share for the current year.

Recursion Pharmaceuticals Profile (Free Report)

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.

Featured Articles Five stocks we like better than Recursion Pharmaceuticals The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report).

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINESchrodinger, Inc. $SDGR Shares Purchased by Amova Asset Management Americas Inc.

NEXT HEADLINE »Amova Asset Management Americas Inc. Purchases 438,930 Shares of Klarna Group plc $KLAR

Recursion Pharmaceuticals (RXRX - Free Report) ended the recent trading session at $3.34, demonstrating a +1.21% change from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 0.38%. Meanwhile, the Dow gained 0.02%, and the Nasdaq, a tech-heavy index, added 0.9%.

The stock of biotechnology company has risen by 0.3% in the past month, lagging the Medical sector's gain of 4.34% and the S&P 500's gain of 1.27%.

The investment community will be closely monitoring the performance of Recursion Pharmaceuticals in its forthcoming earnings report. The company is forecasted to report an EPS of -$0.25, showcasing a 39.02% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $11.99 million, down 37.64% from the prior-year quarter.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.99 per share and a revenue of $54.08 million, representing changes of +31.25% and -27.59%, respectively, from the prior year.

It is also important to note the recent changes to analyst estimates for Recursion Pharmaceuticals. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As of now, Recursion Pharmaceuticals holds a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 163, this industry ranks in the bottom 34% of all industries, numbering over 250.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

An updated edition of the May 18, 2026, article.

The global oncology market is evolving rapidly, fueled by rising cancer incidence, an aging population and continued scientific innovation. According to the American Cancer Society, the United States is projected to record nearly 2.1 million new cancer cases and more than 626,000 cancer-related deaths in 2026. Worldwide, increasing exposure to lifestyle risk factors such as smoking, obesity and physical inactivity, combined with aging demographics, is driving cancer prevalence and supporting sustained growth in oncology-related healthcare spending.

Meanwhile, breakthroughs in cancer treatment are transforming patient care. Advances in immunotherapy, targeted medicines and personalized cancer vaccines have expanded treatment options well beyond conventional chemotherapy and radiation. Immune-based therapies — including checkpoint inhibitors, CAR-T cell therapies, therapeutic vaccines and oncolytic viruses — harness the immune system to combat cancer more effectively. At the same time, targeted therapies improve treatment precision by addressing specific genetic and molecular alterations, while personalized vaccines are paving the way for individualized care.

Emerging technologies such as genomic sequencing, artificial intelligence and machine learning are speeding biomarker discovery, refining patient selection and enabling earlier, more accurate diagnosis. While a universal cure remains out of reach, continued improvements in survival rates and clinical outcomes across multiple cancer types highlight the progress achieved, particularly through earlier detection and timely intervention.

Pharmaceutical companies continue to prioritize oncology through increased investment and pipeline expansion. Industry leaders such as Novartis (NVS - Free Report) , AstraZeneca (AZN - Free Report) , J&J (JNJ - Free Report) , Pfizer (PFE - Free Report) , AbbVie, Merck, Bristol Myers Squibb and Eli Lilly are expanding oncology pipelines with advanced modalities such as antibody-drug conjugates (ADCs), bispecific antibodies and next-generation immuno-oncology therapies. Smaller biotech firms also remain critical innovation drivers, often developing novel platforms and drug targets that support partnerships, licensing deals and M&A activity.

Supported by ongoing innovation, favorable reimbursement trends and expanding treatment options, oncology remains one of the most durable and compelling segments of the global healthcare industry for long-term investors.

With our thematic screens, you can easily spot stocks tied to trends shaping the future of investing. For those looking to gain exposure to the oncology space, companies such as Autolus Therapeutics (AUTL - Free Report) , NextCure (NXTC - Free Report)  and Recursion Pharmaceuticals (RXRX - Free Report) may be worth evaluating as part of a forward-looking portfolio strategy.

Explore 36 cutting-edge investment themes with Zacks Thematic Investing Screens and uncover your next big opportunity.

3 Cancer Stocks in FocusA commercial-stage company, Autolus is primarily focused on developing, manufacturing and marketing next-generation T cell therapies targeting cancer and autoimmune diseases. Autolus has a marketed therapy, Aucatzyl (obecabtagene autoleucel or obe-cel), a CD19-directed CAR-T therapy approved in the United States and United Kingdom for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). Aucatzyl has seen a strong launch in the United States backed by market share gains. The launch in the United Kingdom, which began in January, is off to a strong start. The company has guided 2026 Aucatzyl net product revenues of $120-$135 million, up from approximately $74 million in 2025.

Beyond its marketed therapy, Autolus is pursuing a "pipeline-in-a-product" strategy by expanding obe-cel into several additional indications. Phase II pivotal studies are ongoing in pediatric relapsed or refractory B-cell precursor ALL and severe lupus nephritis patients, while a phase I study is being conducted for progressive multiple sclerosis.

Autolus has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

NextCure is a clinical-stage biotech focused on developing targeted therapies to treat cancer. Management has concentrated resources on two lead ADC programs while seeking strategic partners for several earlier-stage assets.

The company's lead asset is SIM0505, a CDH6-targeted antibody-drug conjugate (ADC) licensed from Simcere Zaiming. NextCure owns worldwide commercialization rights outside China, Hong Kong, Macau and Taiwan, which are retained by Simcere. SIM0505 is being evaluated in a phase I study across multiple advanced solid tumors, with a particular emphasis on platinum-resistant ovarian cancer (PROC). The FDA has granted Fast Track designation to SIM0505 for women with PROC.

Early dose-escalation data presented at ASCO 2026 demonstrated encouraging antitumor activity in heavily pretreated gynecologic cancer patients. The data showed an objective response rate (ORR) of 55% for gynecologic cancers (ovarian cancer and uterine serous carcinoma) and 52.9% for ovarian cancer.

NextCure's second major program is LNCB74, a B7-H4-targeted ADC being co-developed with LigaChem Biosciences. B7-H4 is an attractive oncology target because it is highly expressed in several difficult-to-treat cancers. LNCB74 is being evaluated in a phase I study for the potential treatment of advanced solid tumors.

NXTC has a Zacks Rank #2.

Recursion Pharmaceuticals is a clinical-stage TechBio company that decodes biology and chemistry to industrialize drug discovery. Recursion is using its proprietary technology to build a novel pipeline of candidates, with an initial focus on Precision Oncology and Rare Diseases. RXRX currently has no approved commercial cancer products.

Recursion's most advanced wholly owned oncology asset is REC-1245, a potential first-in-class RBM39 degrader, being evaluated in the phase I/II DAHLIA study for the treatment of biomarker-enriched solid tumors and lymphoma. Early clinical data have been encouraging, showing a favorable safety profile, predictable dose-dependent pharmacokinetics and no dose-limiting toxicities during dose escalation. Other candidates being developed include REC-617 (CDK7 inhibitor for advanced solid tumors), REC-4539 (an LSD1 inhibitor for solid tumors) and REC-3565 (a MALT1 inhibitor for B-cell malignancies), in separate early-stage studies.

RXRX has a Zacks Rank #2.

As the biotechnology landscape shifts toward personalized medicine and advanced computing, investors are weighing established leaders against emerging tech-driven disruptors. Moderna (MRNA +9.99%) and Recursion Pharmaceuticals (RXRX +3.54%) offer two distinct paths forward.

Moderna pioneered the use of messenger RNA to deliver genetic instructions to cells, while Recursion uses machine learning to identify new drug candidates. Both companies are currently operating at a net loss while investing heavily in research, making them high-stakes options for those tracking the future of the healthcare sector.

The case for ModernaModerna focuses on developing mRNA medicines that instruct the human body to produce proteins to prevent or treat various diseases. The company is diversifying its pipeline into immuno-oncology and rare diseases through strategic collaborations with partners such as Merck & Co. (MRK +3.13%) and Recordati. These partnerships are vital for its research and commercialization efforts as it moves beyond its initial focus on respiratory viruses.

In FY 2025, the company reported revenue of more than $1.9 billion, a decrease of approximately 40% from the previous fiscal year. This decline contributed to a net loss of roughly $2.8 billion for the period, though it was narrower than in fiscal 2024.

On its December 2025 balance sheet, the debt-to-equity ratio was approximately 0.2x. This ratio measures total debt relative to shareholders’ equity, with lower ratios typically indicating less reliance on borrowed money. Free cash flow, calculated as cash from operations minus capital expenditures, was nearly $2.1 billion negative.

The case for Recursion PharmaceuticalsRecursion Pharmaceuticals operates as a clinical-stage "TechBio" company that uses its AI-native operating system to discover new medicines. It maintains critical partnerships with major biotech stocks and pharmaceutical firms like Roche, Genentech, and Sanofi (SNY +3.67%). These collaborations provide funding and validation for its automated biological research platform as it targets high-unmet-need areas like neuroscience.

In FY 2025, the company generated revenue of approximately $74.7 million, marking an increase of about 27% year over year. Despite this growth, it recorded a net loss of nearly $645 million for the fiscal period, as the firm continued to invest heavily in its digital and laboratory infrastructure.

As of its December 2025 balance sheet, the company maintained a debt-to-equity ratio of near 0.1x, indicating a strong position to meet short-term liabilities. Free cash flow for the period was approximately negative $378 million, reflecting the high costs of maintaining its data-generation capabilities and proprietary hardware.

Risk profile comparisonModerna faces intense competitive pressure from large manufacturers like Pfizer (PFE +1.78%), Sanofi, and GSK (GSK +4.66%). Changes in regulatory policies or vaccine recommendations can significantly shift demand and disrupt financial forecasts. While a major $2.25 billion lawsuit with Genevant and Arbutus Biopharma Corp (ABUS +2.96%) was settled in March 2026, the company still navigates industry-wide uncertainty regarding mRNA intellectual property. Success depends on high-risk clinical execution across its oncology and rare disease programs.

Recursion Pharmaceuticals relies heavily on its unproven AI-enabled discovery platform, where any inaccuracies in predictive modeling could lead to failed drug candidates. The business is also dependent on strategic partners such as Roche to fund research, so any termination of these deals would harm operations. Additionally, the company faces risks from potential cyber-attacks on its proprietary biological data sets and its reliance on third-party cloud infrastructure provided by Amazon.com Inc (AMZN +0.55%).

Valuation comparisonModerna offers a more established revenue base and a lower sales multiple, whereas Recursion Pharmaceuticals is a higher-growth, earlier-stage bet with a steeper price-to-sales valuation.

MetricModernaRecursion PharmaceuticalsSector BenchmarkForward P/En/an/a389.1xP/S ratio12.9x26.8xn/aSector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

The COVID-19 vaccine developed by Moderna was a proof of concept of the power of mRNA research to quickly produce new treatments. Unfortunately for Moderna, the decline in people getting the COVID vaccine, along with plenty of competitors with their own vaccines, has hammered the business’s revenue in recent years. A more recent RSV vaccine reached the market after competing vaccines, resulting in less-than-robust adoption.

Still, Moderna has some 25 mRNA Development candidates across 35 development programs in its portfolio. Seeing those come to market and make a meaningful impact on the business will take some time, however. Next year is likely when one or more of the products will get to market, and it is probably not until 2028 that significant revenue will hit the top line. In fiscal 2026, Moderna  is seen posting modest sales growth of about 8% to get close to $2.1 billion revenue with a much narrower net loss of around $1.8 billion.

Recursion, meanwhile, is still in development phase, with lumpy revenue stemming from milestone payments from partners like Sanofi. For fiscal 2026, revenue is expected to decline about 11% due to lower milestone payments. The business is making progress with its AI-based discovery platform. In the first quarter, management touted its first clinical proof of concept with its polyp-related treatment, REC-4881 allosteric MEK1/2 inhibitor focused on FAP. It showed a significant reduction in precancerous polyps, a major driver of the disease’s progressive nature. Still, significant revenue for the business is seen as years away.

So which cutting-edge biotech is the stock to buy? Moderna has come to market with proven treatments derived from its mRNA platform, and Recursion is still hoping to prove its model. Moderna may be in a sales and development lull for 2026, but odds are a proven formula will provide itself again. Moderna gets the nod here. 

Choosing between Recursion Pharmaceuticals (RXRX +4.83%) and Summit Therapeutics (SMMT +2.21%) requires weighing the broad potential of artificial intelligence against the specific clinical prospects of a high-potential oncology drug candidate.

Both companies operate in the high-stakes world of biotechnology, but they take very different paths toward drug development. While Recursion focuses on an industrial-scale platform to find many targets, Summit is betting heavily on the success of a single, promising antibody therapy.

Recursion Pharmaceuticals operates as a TechBio company, using its proprietary Recursion OS to automate biological experiments and analyze them with artificial intelligence. The company generates vast amounts of proprietary data to identify potential treatments for oncology, rare diseases, and neuroscience. It works with several major biotech stocks through strategic collaborations, including Roche (RHHBY +1.62%), Genentech, Takeda (TAK +0.44%), Bayer (BAYRY 1.73%), Merck (MRK +0.56%), and Sanofi (SNY +1.12%). Customer concentration in these large-scale partnerships adds a layer of risk to the business, as revenue depends on the continued health of these specific alliances.

In fiscal 2025, revenue reached nearly $74.7 million, good for growth of about 26.9% year over year. Despite this growth, the company reported a net loss of close to $644.8 million. This reflects the high cost of maintaining its massive computing infrastructure and advancing a broad pipeline of investigational medicines through various stages of development.

As of Recursion’s December 2025 balance sheet, the debt-to-equity ratio stands at roughly 0.1x, which measures total debt against shareholder equity and indicates a very low level of borrowing. The current ratio is approximately 5.5x, meaning the company has five and a half times more short-term assets than short-term liabilities to cover its immediate obligations. Free cash flow was negative at nearly $378.3 million for the year, which is pretty common for clinical-stage companies investing heavily in future research.

The case for Summit TherapeuticsSummit Therapeutics is a biopharmaceutical company primarily focused on developing ivonescimab, a bispecific antibody designed to treat various types of solid tumors. The company’s core strategy revolves around a licensing agreement with Akeso (AKESF 4.54%), which grants Summit the rights to develop and commercialize this lead candidate in major global territories including North America and Europe. Because the company’s future depends almost entirely on this one drug, its commercial success is highly concentrated on clinical trial outcomes and the relationship with its supply partner.

In fiscal 2025, the company reported no revenue, as it doesn’t yet have products for sale. The net loss for the year was approximately $1.1 billion, a significant increase from previous periods. This high level of spending is largely due to the expensive late-stage clinical trials required to prove the efficacy and safety of ivonescimab to regulatory agencies.

As of Summit’s December 2025 balance sheet, the debt-to-equity ratio is zero, meaning the company carries no debt relative to its shareholder equity. Its current ratio is nearly 9.9x, which shows a very strong ability to meet short-term financial commitments with existing cash and assets. Free cash flow for the period was negative at close to $240.2 million, reflecting the ongoing costs of drug development without any incoming product revenue.

Risk profile comparisonRecursion Pharmaceuticals faces risks related to its significant history of operating losses, including an accumulated deficit of roughly $2.1 billion. There is no guarantee that its AI-driven platform will successfully produce approved drugs, and the company requires substantial new capital to continue its operations. Furthermore, the business relies on third-party manufacturers and strategic partners, and any issue with these relationships or disruptions in the supply chain could hinder development.

Summit Therapeutics is heavily exposed to concentration risk, as its business value is almost entirely tied to ivonescimab. If this single candidate fails in clinical trials or does not receive regulatory approval, the company would be would be up a creek without a paddle. Additionally, Summit has massive future financial obligations to its partner Akeso, including potential payments of up to $4.56 billion, and faces stiff competition from established oncology giants like Merck and Bristol-Myers Squibb (BMY +1.81%).

Valuation comparisonRecursion Pharmaceuticals currently trades at a high multiple of its revenue, while Summit Therapeutics has no price-to-sales ratio due to its lack of product sales.

MetricRecursion PharmaceuticalsSummit TherapeuticsP/S ratio19.3N/ASector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?I think Recursion Pharmaceuticals looks more attractive here. It posted a significantly smaller loss in its most recent fiscal year, and the company has multiple big-name partnerships currently employing its proprietary system. There is no guarantee Recursion's platform is going to produce anything that moves the needle, but I like that it has diversification among clients (and therefore, presumably among drugs). Plus, I don't think pharma giants like Merck or Sanofi are at risk of going out of business.

On the other hand, Summit is basically betting the house on ivonescimab. That concentration risk is not a thing I would go in for. It has plenty of dry powder, sure, but it's all being directed toward one place. If this single drug candidate fails, I'm not sure if Summit could pivot to something else, and even if it could, how long that might take. Furthermore, Summit relies on a single partnership, unlike Recursion, which has multiple companies it's teaming up with.

Recursion Pharmaceuticals (RXRX - Free Report) closed the most recent trading day at $3.18, moving -3.34% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.57%. Elsewhere, the Dow gained 0.64%, while the tech-heavy Nasdaq lost 1.15%.

Coming into today, shares of the biotechnology company had gained 13.84% in the past month. In that same time, the Medical sector gained 4.28%, while the S&P 500 gained 2.14%.

The upcoming earnings release of Recursion Pharmaceuticals will be of great interest to investors. The company is expected to report EPS of -$0.25, up 39.02% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.99 million, down 37.64% from the year-ago period.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.99 per share and a revenue of $54.08 million, representing changes of +31.25% and -27.59%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for Recursion Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Recursion Pharmaceuticals is currently sporting a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 151, which puts it in the bottom 39% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.

Recursion Pharmaceuticals, Inc. remains a Hold as competitive risks persist and the company is years away from meaningful pipeline revenue. RXRX's AI-driven Recursion OS platform shows strong potential, but has yet to demonstrate a clear competitive edge or superior scalability versus well-funded peers. Share dilution and accelerating cash burn threaten RXRX shareholder value, with at least 18-24 months before potential pipeline revenue and likely further capital raises.

Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will complete his current term through June 2026 and does not intend to seek re-election to the Company’s Board of Directors.  

“I greatly appreciated Chris’s partnership during my transition into the CEO role at Recursion and am pleased that he will remain an advisor to the company moving forward,” said Najat Khan, Ph.D., Chief Executive Officer and President of Recursion. “We remain focused on continuity and long-term value creation at Recursion. With a strong foundation and team in place, I’m excited about what we will deliver to shareholders and patients - advancing both our internal and partnered pipeline while translating our AI-powered platform into meaningful therapeutic impact.”

“I’d like to thank Chris for his vision in founding Recursion and for his meaningful contributions to the field,” said Rob Hershberg, M.D., Ph.D., Vice-Chair of the Board and Lead Independent Director. “Chris has played an important role in supporting our evolution over the last several months as an advisor, founder, and leader, and we are deeply grateful for his partnership and guidance.”

“Being a founder of Recursion and participating in building the company with an amazing team has been one of the most rewarding journeys that I could have imagined,” said Chris Gibson, Ph.D., Founder and Chair (advisor) of Recursion. “I look forward to watching Recursion flourish under Najat’s leadership and am excited to continue my connection to the company as a strategic advisor. I am excited about Recursion’s future and, as always, will be cheering for Recursion with a full heart.”

About Recursion

Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.

Recursion’s platform infrastructure is anchored in Salt Lake City, Utah and Milton Park, Oxfordshire, where its automated biology and chemistry laboratories generate proprietary data at industrial scale. Recursion also maintains offices in New York, Montréal, and London, three global hubs for talent and leadership at the intersection of AI and scientific innovation. Learn more at www.recursion.com, or connect on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements regarding Recursion’s future plans, strategy, growth opportunities, leadership, and ability to advance its mission, platform, pipeline, and partnerships. These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These and other risks are described in Recursion’s filings with the U.S. Securities and Exchange Commission. Recursion undertakes no obligation to update any forward-looking statements except as required by law.

SALT LAKE CITY, May 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates highlighting strong continued pipeline execution, clinical progress and platform advancement, as well as financial results for its first quarter ended March 31, 2026.

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2026 Earnings Call Transcript

• Recursion Pharmaceuticals shares are retreating from recent levels. Why is RXRX stock falling?

The company is scheduled to provide an update about the FDA decision in the second half of the year. And, there is potential upside to the stock, according to Needham.

The Recursion Pharmaceuticals Analyst: Analyst Gil Blum maintained a Buy rating and price target of $8.

The Recursion Pharmaceuticals Thesis: The company reported non-GAAP operating expenditure of $85 million for the first quarter, representing a decline of around 30% year-on-year, with a fiscal year cash burn guidance of less than $390 million, Blum said in the note.

Check out other analyst stock ratings.

The update on the pivotal trial design for REC-4881 will be the "next value driver" for Recursion Pharmaceuticals, the analyst stated.

"Given the lack of regulatory precedent in FAP, Recursion intends to focus on natural history data, identification of appropriate patient populations, optimizing dose escalation, and defining clinically meaningful endpoints," Blum wrote.

The company intends to leverage its AI-enabled clinical platform to support registrational planning and accelerate enrolment, he added.

"Recursion also reported initial REC-1245 safety and PK data across four dose cohorts, showing mostly low-grade AEs (adverse events)," the analyst further noted.

RXRX Price Action: Shares of Recursion Pharmaceuticals had declined by 3.85% to $3.30 at the time of publication on Thursday.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

SALT LAKE CITY, May 19, 2026 (GLOBE NEWSWIRE) -- Altitude Lab, the platform-first biotech-startup accelerator founded by Recursion (NASDAQ: RXRX), announced today that its portfolio companies have collectively raised more than $205 million in early-stage funding since the program's launch in 2020. The milestone reflects a portfolio of companies advancing into clinical trials, signing deals with global pharma, and commercializing platform technologies reshaping the boundaries of early-stage biotech despite this difficult funding climate.

Dr. Joshua Schiffman, CEO/Co-founder of Peel Therapeutics, credits their success to initial support from Altitude Lab, "With Altitude Lab serving as our biotech basecamp, we now have become a clinical stage biotech with encouraging initial results and multiple phase trials both in Utah and throughout the country."

2025 proved pivotal for Altitude Lab's startups, with inaugural cohort alumni Peel Therapeutics and Rebel Medicine raising Series A rounds to accelerate clinical development. These companies continue to build the backbone of Salt Lake City's maturing biotech ecosystem and define the Mountain West region on a national stage.

Portfolio Momentum & Milestones:

Peel Therapeutics: Closed a fully subscribed $20 million Series A. Lead asset PEEL-224, an optimized TOP1 inhibitor, demonstrated a 68% disease control rate with limited GI toxicity in heavily pre-treated solid tumor patients (N=47) in its Phase 1A trial. Proceeds from the Series A will support the company's ongoing Phase 1B/2 clinical development in metastatic colorectal cancer and pediatric solid tumors, as well as advance Peel’s broader oncology pipeline.

Rebel Medicine: Closed a $7.5M Series A led by Crocker Ventures and received FDA IND clearance for Alevatrix, its long-acting bupivacaine reformulation designed to provide up to 72 hours of non-opioid pain relief. Rebel is running its first-in-human Phase 2 trial evaluating Alevatrix as an opioid-sparing therapy.

Leash Bio: Signed a multi-target agreement with Monte Rosa Therapeutics to accelerate discovery of degraders for difficult-to-drug targets. Leash's platform had identified tractable material for over 500 targets prior to the partnership, enabling compounds to reach Monte Rosa's team in a fraction of the typical timeline.

Intactis Bio: Raised $250K from Nucleus Fund, post-investment from RPV, and achieved a landmark milestone: lab-grown neurons derived from iPSCs successfully demonstrated encoding and decoding of language and math operations, with continuous learning during inference, a structural advantage over GPUs.

Sethera Therapeutics: Entered award negotiations for a significant and highly competitive CDMRP Breast Cancer Research Program Breakthrough Award. Sethera continued strengthening its Scientific Advisory Board with the addition of a Nobel Laureate in Physiology and/or Medicine, joining members Jeffery W. Kelly (Scripps Research), Alexander M. Klibanov (MIT), and Dr. Robert Langer (MIT).

3Helix: Announced a partnership with BASF, successfully launching NeoHelix™ Regenerate, the first precision peptide inspired by 3Helix's proprietary collagen-hybridizing peptide (CHP) technology. In clinical studies, the ingredient demonstrated a 41% reduction in damaged collagen and a 65% increase in hyaluronic acid levels after 56 days.

Calycia Biosciences: A University of Utah spin-out and part of Altitude Lab’s new cohort, won Altitude Lab's 2026 Demo Day and secured $400,000 in pre-seed funding from University of Utah Ventures (operated by EPIC Ventures) and Cumming Foundation.

Leadership Transition

Altitude Lab has appointed Kapil Sharma as Interim Executive Director. Sharma has spent four years expanding the organization's national visibility and network of investors and strategic partners to more than 200 firms.

"Our mission remains unchanged: to build a new breed of biotech companies and a nationally interconnected ecosystem, while strengthening Salt Lake City's position as an upcoming biotech hub," said Sharma.

Chandana Haque, co-founder and former Executive Director, will continue to support the organization as a board member.

About Altitude Lab

Altitude Lab is developing a new generation of biotech founders to seed the next cycle of health care innovation. Headquartered in Salt Lake City, Utah, Altitude Lab is a Recursion startup accelerator focused on launching early-stage life science companies, with an emphasis in TechBio and platform-based technology commercialization. The Recursion Charitable Foundation, DBA Altitude Lab, operates as a 501(c)(3) nonprofit and is a large contributor to Utah's BioHive.

Learn more at altitudelab.org or connect on X and LinkedIn.

Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in an upcoming investor conference:

Goldman Sachs 47th Annual Global Healthcare Conference — Tuesday, June 9, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. 
About Recursion
Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.
Recursion’s platform infrastructure is anchored in Salt Lake City, Utah and Milton Park, Oxfordshire, where its automated biology and chemistry laboratories generate proprietary data at industrial scale. Recursion also maintains offices in New York, Montréal, and London, three global hubs for talent and leadership at the intersection of AI and scientific innovation. Learn more at www.recursion.com, or connect on X and LinkedIn.
Media Contact
[email protected]
Investor Contact
[email protected]

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

9.22K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.